Provided by Tiger Trade Technology Pte. Ltd.

Cabaletta Bio

1.89
-0.0300-1.56%
Post-market: 1.930.0400+2.12%19:56 EDT
Volume:8.54M
Turnover:16.24M
Market Cap:321.30M
PE:-1.23
High:1.97
Open:1.92
Low:1.86
Close:1.92
52wk High:4.23
52wk Low:1.86
Shares:170.00M
Float Shares:141.48M
Volume Ratio:1.62
T/O Rate:6.03%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5420
EPS(LYR):-2.1000
ROE:-93.20%
ROA:-48.19%
PB:1.53
PE(LYR):-0.90

Loading ...

U.S. Earnings Preview: Before Market Open May 13

Dow Jones
·
May 13

Top News Today: Stocks Mixed, Oil Rises After Hot Inflation Data

Dow Jones
·
May 13

Cabaletta Bio Inc expected to post a loss of 40 cents a share - Earnings Preview

Reuters
·
May 11

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Cabaletta Bio (CABA), Inspire Medical Systems (INSP) and UnitedHealth (UNH)

TIPRANKS
·
May 06

Cabaletta Bio Maintained at Buy as Emerging Rese-cel Data Support Preconditioning-Free Potential; $13 Price Target Reaffirmed

TIPRANKS
·
May 05

Cabaletta Bio financing overhang concerns should be addressed, says Cantor

TIPRANKS
·
May 04

Cabaletta Bio Price Target Maintained With a $30.00/Share by Cantor Fitzgerald

Dow Jones
·
May 04

Cabaletta Bio publishes corporate presentation on rese-cel CD19 CAR-T autoimmune disease program

Reuters
·
May 04

Cabaletta Bio Prices $150 Million Stock Offering

MT Newswires Live
·
May 04

Cabaletta Bio Inc - Purchase Price for Common Stock Set at $2.90 per Share

THOMSON REUTERS
·
May 04

Press Release: Cabaletta Bio Announces Pricing of $150 Million Underwritten Offering

Dow Jones
·
May 04

Cabaletta Bio reports promising RESET-PV and RESET-SLE data

TIPRANKS
·
May 04

Cabaletta Bio reports rese-cel activity without preconditioning in RESET-PV pemphigus trial

Reuters
·
May 04

Analysts Offer Insights on Healthcare Companies: Definium Therapeutics (DFTX) and Cabaletta Bio (CABA)

TIPRANKS
·
Apr 29

Cabaletta Bio signs 10-year rese-cel commercial supply deal with Cellares

Reuters
·
Apr 28

Cabaletta Bio and Cellares Announce 10-Year Commercial Supply Agreement for Rese-Cel

THOMSON REUTERS
·
Apr 28

Cabaletta Bio to present rese-cel pemphigus data without preconditioning at ASGCT 2026

Reuters
·
Apr 28

Cabaletta Bio: RESET-MG Data and Differentiated Autoimmune Strategy Underpin Buy Rating and Upside Potential

TIPRANKS
·
Apr 21

Cabaletta Bio Updates rese-cel Autoimmune Therapy Development Plans

TIPRANKS
·
Apr 20

Cabaletta Bio posts corporate presentation on CD19 CAR-T candidate rese-cel in autoimmunity

Reuters
·
Apr 20